DADC
RARE icon

D.A. Davidson & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

D.A. Davidson & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$6K – 1787
2017
Q2 		$6K Hold
100
– – ﹤0.01% 2173
2017
Q1 		$6K Hold
100
– – ﹤0.01% 2142
2016
Q4 		$7K Buy
+100
New +$7.09K ﹤0.01% 2188
2015
Q3 		– Sell
-70
Closed -$7K – 2266
2015
Q2 		$7K Hold
70
– – ﹤0.01% 1954
2015
Q1 		$4K Hold
70
– – ﹤0.01% 1945
2014
Q4 		$3K Buy
+70
New +$3.21K ﹤0.01% 1993

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

D.A. Davidson & Co's RARE Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2017, closing a stake of 100 shares — an estimated $6K sold.

D.A. Davidson & Co first reported a position in RARE in Q4 2014 and held it in 6 quarters. The position peaked at $7K in Q4 2016. 154 funds tracked by Wall St. Rank hold RARE as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Ultragenyx Pharmaceutical position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 100 Ultragenyx Pharmaceutical shares in Q3 2017, an estimated $6K.
  • D.A. Davidson & Co first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and held it in 6 quarters.
  • D.A. Davidson & Co's Ultragenyx Pharmaceutical position peaked at $7K in Q4 2016.
  • 154 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.